Weight loss efficacy of semaglutide
Pro Research Analysisby 
Searched over 200M research papers
Semaglutide Weight Loss Efficacy in Obesity and Overweight Adults
Significant Weight Loss Outcomes with Semaglutide
Multiple large clinical trials and meta-analyses consistently show that semaglutide, especially at a dose of 2.4 mg once weekly, leads to substantial weight loss in adults with overweight or obesity. Across the STEP clinical trial program, individuals without diabetes experienced mean weight reductions of 14.9% to 17.4% over 68 weeks, with 69–79% achieving at least 10% weight loss and 51–64% achieving at least 15% weight loss, compared to much lower rates with placebo 13. In the STEP 5 trial, weight loss was sustained over two years, with a mean reduction of 15.2% at 104 weeks versus 2.6% for placebo . The SELECT trial further demonstrated that weight loss with semaglutide was maintained for up to four years, with a mean reduction of 10.2% at 208 weeks, compared to 1.5% for placebo .
Efficacy in Non-Diabetic and Diabetic Populations
Semaglutide is effective for weight loss in both non-diabetic and diabetic populations, though the magnitude of weight loss is generally greater in those without diabetes. In non-diabetic adults, meta-analyses report an average weight loss of 10–12% compared to placebo, with reductions in body mass index and waist circumference also observed 4910. In adults with type 2 diabetes, weight loss is somewhat less but still clinically meaningful, with a mean reduction of 9.6% over 68 weeks .
Dose, Duration, and Administration Route
Higher weekly doses and longer treatment durations are associated with greater weight loss. Subcutaneous semaglutide at 2.0 mg or more once weekly is recommended for optimal results, and benefits are enhanced when combined with lifestyle interventions 19. Oral semaglutide also shows positive effects on weight loss, especially at the maximum dose of 14 mg, maintaining efficacy similar to the injectable form 68.
Comparison with Other Treatments
Semaglutide outperforms other anti-obesity medications, including liraglutide, in head-to-head trials. For example, at 52 weeks, semaglutide at higher doses resulted in greater weight loss (up to 13.8%) compared to liraglutide (7.8%) and placebo (2.3%) . These findings have led to regulatory approval of semaglutide (Wegovy) for chronic weight management .
Safety and Tolerability
The most common side effects of semaglutide are gastrointestinal, such as nausea and diarrhea, which are usually mild to moderate and tend to decrease over time. Serious adverse events are less frequent with semaglutide than with placebo, and the overall safety profile is considered acceptable for long-term use 1259+1 MORE.
Additional Health Benefits
Beyond weight loss, semaglutide improves cardiometabolic risk factors, including blood pressure, lipid profiles, and markers of inflammation. These benefits contribute to improved physical function and quality of life for individuals with obesity 1310.
Conclusion
Semaglutide is highly effective for weight loss in adults with overweight or obesity, with sustained results over several years and additional health benefits. Its efficacy is robust across different populations and administration routes, and it is generally well tolerated, making it a leading option for chronic weight management.
Sources and full results
Most relevant research papers on this topic